| Literature DB >> 35847243 |
Myung Woo Na1, Se Yun Jeong1, Yoon-Joo Ko2, Dong-Min Kang3, Changhyun Pang4, Mi-Jeong Ahn3, Ki Hyun Kim1.
Abstract
The fruit of Tetradium ruticarpum, known as Evodiae Fructus, is a traditional herbal medicine used to treat gastric and duodenal ulcers, vomiting, and diarrhea. The traditional usage can be potentially associated with the antibacterial activity of T. ruticarpum fruits against Helicobacter pylori. However, so far, the antibacterial activity of T. ruticarpum fruits and antibacterial components against H. pylori has not been investigated despite the traditional folk use. The current study was conducted to investigate the bioactive chemical components of T. ruticarpum fruits and evaluate their antibacterial activity against H. pylori. Phytochemical investigation of the EtOH extract of T. ruticarpum fruits led to the isolation and identification of nine compounds (1-9), including phellolactone (1), the absolute configuration of which has not yet been determined. The chemical structures of the isolated compounds were elucidated by analyzing the spectroscopic data from one-dimensional (1D) and two-dimensional (2D) NMR and high-resolution electrospray ionization mass spectrometry (HR-ESIMS) experiments. Specifically, the absolute configuration of compound 1 was established by the application of computational methods, including electronic circular dichroism (ECD) calculation and the NOE/ROE-based interproton distance measurement technique via peak amplitude normalization for the improved cross-relaxation (PANIC) method. In the anti-H. pylori activity test, compound 3 showed the most potent antibacterial activity against H. pylori strain 51, with 94.4% inhibition (MIC50 and MIC90 values of 22 and 50 μM, respectively), comparable to that of metronidazole (97.0% inhibition, and MIC50 and MIC90 values of 17 and 46 μM, respectively). Moreover, compound 5 exhibited moderate antibacterial activity against H. pylori strain 51, with 58.6% inhibition (MIC50 value of 99 μM), which was higher than that of quercetin (34.4% inhibition) as a positive control. Based on the bioactivity results, we also analyzed the structure-activity relationship of the anti-H. pylori activity.Entities:
Year: 2022 PMID: 35847243 PMCID: PMC9280968 DOI: 10.1021/acsomega.2c02380
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Chemical structures of compounds 1–9.
1H (850 MHz) and 13C NMR (212.5 MHz) Data for Compound 1 in CD3OD (δ ppm)a
| position | δH ( | δC |
|---|---|---|
| 2 | 176.2 C | |
| 3 | 4.55 s | 70.1 CH |
| 4 | 75.5 C | |
| 5α | 4.41 d (10.0) | 72.3 CH2 |
| 5β | 4.26 d (10.0) | |
| 6a | 4.39 d (11.5) | 64.6 CH2 |
| 6b | 4.43 d (11.5) | |
| 1′ | 120.4 C | |
| 2′ | 7.59 d (2.0) | 112.3 CH |
| 3′ | 147.4 C | |
| 4′ | 151.8 C | |
| 5′ | 6.86 d (8.0) | 114.6 CH |
| 6′ | 7.61 dd (8.0, 2.0) | 123.9 CH |
| 7′ | 166.2 C | |
| 3′-OCH3 | 3.91 s | 54.9 CH3 |
Coupling constants (Hz) are given in parentheses.
13C NMR data were assigned based on HSQC and HMBC experiments.
Figure 2(A) Key 1H–1H COSY (blue hyphen) and HMBC (red forward-curved arrow) correlations for 1. (B) Key nuclear Overhauser effect spectroscopy (NOESY) correlations of 1.
Figure 3Optimized 3D structures of 1A and 1B with predicted interproton distance between H-3 and H-6b.
Figure 4Experimental and calculated ECD spectra of compound 1.
Anti-H. pylori Activity of Compounds 1–9 against H. pylori Strain 51 Treated with 100 μM of Each Compound
| compound | inhibition (%) | MIC50 (μM) | MIC90 (μM) |
|---|---|---|---|
| 1 | 8.1 | ||
| 2 | 0.0 | ||
| 3 | 94.4 | 22 | 50 |
| 4 | 14.8 | ||
| 5 | 58.6 | 99 | >100 |
| 6 | 15.7 | ||
| 7 | 20.0 | ||
| 8 | 7.1 | ||
| 9 | 16.1 | ||
| quercetin | 34.4 | ||
| metronidazole | 97.0 | 17 | 46 |
Positive controls.